Press Releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2001 Press Releases

Listed below are all of the QLT press releases available for the year you have selected.

December 19	Paul J. Hastings Named CEO of QLT	PDF version
November 2	Novartis Ophthalmics and QLT Update Status of Visudyne ™ Reimbursement Process	PDF version
October 24	QLT Appoints Chief Financial Officer	PDF version
October 24	QLT Announces Third Quarter Financial Results	PDF version
October 19	Visudyne ™ Therapy Reimbursement in U.S. Expanded to Include Patients with Occult Form of Wet Age-Related Macular Degeneration	PDF version
October 11	QLT Announces Visudyne ™ Sales for Third Quarter of 2001	PDF version
October 1	QLT on Track to Meet Financial Targets	PDF version
September 10	Novartis Ophthalmics and QLT File Canadian Submission for Expansion of Visudyne ™ Approval	PDF version
September 7	Novartis Ophthalmics and QLT File Submission with the European Medicines Agency to Expand the Use of Visudyne ™ in AMD	PDF version
September 5	QLT Appoints Vice President, Marketing & Sales Planning	PDF version
August 23	Novartis Ophthalmics and QLT Announce FDA Approval of Visudyne ™ as the First Drug Treatment for Pathologic Myopia and Ocular Histoplasmosis	PDF version
August 13	QLT Expands Pipeline with Acquisition of Late-Stage Compound for Multidrug Resistance in Cancer	PDF version
July 26	Novartis Ophthalmics and QLT Announce that Health Canada Approves Expanded Use of Visudyne ™	PDF version
July 25	QLT Announces Financial Results for Second Quarter and First Half of 2001	PDF version
July 23	QLT and Novartis Ophthalmics to Fight Skin Cancer	PDF version
June 7	QLT Enters into Research and License Agreement with Kinetek	PDF version
May 10	Favorable Visudyne ™ Clinical Results Published in American Journal of Ophthalmology Show Benefit in AMD Patients with Occult Disease	PDF version
May 2	QLT Files Supplemental Claims Against Massachusetts Eye and Ear Infirmary in Ongoing Patent Litigation in Response to Issuance of New Patent	PDF version
May 2	Vision Benefit Sustained During Third Year of Visudyne ™ Therapy	PDF version
April 25	QLT Announces First Quarter Financial Results	PDF version
April 25	QLT Reviews Highlights from Annual General Meeting	PDF version
April 19	QLT Announces Visudyne ™ Sales for First Quarter of 2001	PDF version
March 23	EU Commission Approves Expanded Use of Visudyne ™	PDF version
February 8	QLT Announces Fourth Quarter and Year End Results for 2000	PDF version
February 7	Favorable Visudyne ™ Clinical Results Announced for Occult AMD and Pathologic Myopia Patients	PDF version
February 5	FDA Issues Approvable Letter for Expanded Use of Visudyne ™	PDF version
January 30	QLT Receives Notice of Lawsuit	PDF version

Visudyne® is a registered trademark of Novartis AG

Vancouver Web Design by Graphically Speaking